Reversing Dysfunction of CCR9+ Regulatory T Cells by Targeting the IL-21/IL-17 Axis Improves Type 1 Diabetes.

avizakimab (BOS161721) - Boston Pharma

http://www.ncbi.nlm.nih.gov/pubmed/42694947

Lei Yang; Qing He; Shanshan Zhan; Shunfeng Mao; Yuhui Yao; Yulian Xia

Sep 5, 2026